Pioglitazone added to conventional lipid-lowering treatment in familial combined hyperlipidaemia improves parameters of metabolic control: Relation to liver, muscle and regional body fat content

Atherosclerosis

Volumn 195, Issue 1, 2007, Pages

  Thomas, E Louise ^a   Potter, Elizabeth ^b   Tosi, Isabella ^b   Fitzpatrick, Julie ^a   Hamilton, Gavin ^a   Amber, Vian ^a   Hughes, Robert ^a   North, Christopher ^c   Holvoet, Paul ^d   Seed, Mary ^e   Betteridge, D John ^c   Bell, Jimmy D ^a   Naoumova, Rossi P ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Adipose tissue; Intrahepatic fat; Intramyocellular lipids; MRI

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; PIOGLITAZONE; STATIN; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY FAT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FAMILIAL HYPERLIPEMIA; FAT CONTENT; GLUCOSE BLOOD LEVEL; HUMAN; LIVER; MALE; METABOLIC REGULATION; MUSCLE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADIPOSE TISSUE; ADULT; DOUBLE-BLIND METHOD; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; LIPIDS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLES; PLACEBOS; THIAZOLIDINEDIONES;

EID: 35248839502     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.03.043     Document Type: Article

References (47)

1. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., and Motulsky A.G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52 (1973) 1544-1568
2. Hopkins P.N., Heiss G., Ellison R.C., et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 108 (2003) 519-523
3. Aitman T.J., Godsland I.F., Farren B., et al. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 17 (1997) 748-754
4. McNeely M.J., Edwards K.L., Marcovina S.M., et al. Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study. Atherosclerosis 159 (2001) 471-481
5. Ayyobi A.F., McGladdery S.H., McNeely M.J., et al. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 23 (2003) 1289-1294
6. Shoulders C.C., Jones E.L., and Naoumova R.P. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum Mol Genet 13 Spec no. 1 (2004) R149-R160
7. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
8. Betteridge D.J., and Verges B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 48 (2005) 2477-2481
9. Winkler K., Konrad T., Fullert S., et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 26 (2003) 2588-2594
10. Kelly I.E., Han T.S., Walsh K., and Lean M.E. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22 (1999) 288-293
11. Miyazaki Y., Mahankali A., Matsuda M., et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87 (2002) 2784-2791
12. Bajaj M., Suraamornkul S., Piper P., et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89 (2004) 200-206
13. Rasouli N., Raue U., Miles L.M., et al. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 288 (2005) E930-E934
14. Naoumova R.P., Bonney S.A., Eichenbaum-Voline S., et al. Confirmed locus on chromosome 11p and candidate loci on 6q and 8p for the triglyceride and cholesterol traits of combined hyperlipidemia. Arterioscler Thromb Vasc Biol 23 (2003) 2070-2077
15. Kreymann B., Williams G., Ghatei M.A., and Bloom S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2 (1987) 1300-1304
16. Holvoet P., Macy E., Landeloos M., et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem 52 (2006) 760-764
17. Rajala U., Laakso M., Paivansalo M., et al. Low insulin sensitivity measured by both quantitative insulin sensitivity check index and homeostasis model assessment method as a risk factor of increased intima-media thickness of the carotid artery. J Clin Endocrinol Metab 87 (2002) 5092-5097
18. Boizel R., Benhamou P.Y., Lardy B., et al. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care 23 (2000) 1679-1685
19. Holvoet P., Kritchevsky S.B., Tracy R.P., et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 53 (2004) 1068-1073
20. Thomas E.L., Hamilton G., Patel N., et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 54 (2005) 122-127
21. Rico-Sanz J., Thomas E.L., Jenkinson G., et al. Diversity in levels of intracellular total creatine and triglycerides in human skeletal muscles observed by (1)H MRS. J Appl Physiol 87 (1999) 2068-2072
22. Thomas E.L., Saeed N., Hajnal J.V., et al. Magnetic resonance imaging of total body fat. J Appl Physiol 85 (1998) 1778-1785
23. Promrat K., Lutchman G., Uwaifo G.I., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39 (2004) 188-196
24. Arioglu E., Duncan-Morin J., Sebring N., et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 133 (2000) 263-274
25. Carreon-Torres E., Juarez-Meavepena M., Cardoso-Saldana G., et al. Pioglitazone increases the fractional catabolic and production rates of high-density lipoproteins apo AI in the New Zealand White Rabbit. Atherosclerosis 181 (2005) 233-240
26. Sakamoto J., Kimura H., Moriyama S., et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278 (2000) 704-711
27. Lamarche B., Lemieux I., and Despres J.P. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 25 (1999) 199-211
28. Gaziano J.M., Hennekens C.H., O'Donnell C.J., Breslow J.L., and Buring J.E. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 96 (1997) 2520-2525
29. Goldberg R.B., Kendall D.M., Deeg M.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
30. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006) 2572-2581
31. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
32. Thompson G.R., Morrell J., and Wilson P. Dyslipidemia in clinical practice. 2nd ed. (2006), Informa UK Ltd., Oxon
33. Trujillo M.E., and Scherer P.E. Adipose tissue-derived factors: impact on health and disease. Endocr Rev (2006)
34. Sharma A.M., and Staels B. Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 92 (2007) 386-395
35. Cnop M., Havel P.J., Utzschneider K.M., et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46 (2003) 459-469
36. Yu J.G., Javorschi S., Hevener A.L., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51 (2002) 2968-2974
37. Skurk T., Alberti-Huber C., Herder C., and Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92 (2007) 1023-1033
38. Rodenburg J., Vissers M.N., Wiegman A., et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol 47 (2006) 1803-1810
39. van den Akker J.M., Bredie S.J., Diepenveen S.H., et al. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins C-reactive protein and in vivo oxidized LDL. J Nephrol 16 (2003) 238-244
40. Abbink E.J., De G.J., De Haan J.H., et al. Effects of pioglitazone in familial combined hyperlipidaemia. J Intern Med 259 (2006) 107-116
41. Smith S.R., De J.L., Volaufova J., et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 54 (2005) 24-32
42. Hirose H., Kawai T., Yamamoto Y., et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51 (2002) 314-317
43. Basu A., Jensen M.D., McCann F., et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 29 (2006) 510-514
44. Pruchnic R., Katsiaras A., He J., et al. Exercise training increases intramyocellular lipid and oxidative capacity in older adults. Am J Physiol Endocrinol Metab 287 (2004) E857-E862
45. Tamura Y., Tanaka Y., Sato F., et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 90 (2005) 3191-3196
46. Frost G.S., Goff L.M., Hamilton G., et al. Carbohydrate-induced manipulation of insulin sensitivity independently of intramyocellular lipids. Br J Nutr 89 (2003) 365-375
47. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307